Cancer Treatment Reviews
Volume 31, Issue 6 , Pages 491-495 , October 2005

Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma

References 

  1. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001;5:87–107vi
  2. Chang MH. Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Int. 2003;23:309–314
  3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750
  4. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36:S74–S83
  5. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004;127:1372–1380
  6. Oon CJ, Okuda K, Pang R. Primary hepatocellular carcinoma in the Asian Pacific region. Ann Acad Med Singapore. 1980;9:190–192
  7. Lee NW, Wong J, Ong GB. The surgical management of primary carcinoma of the liver. World J Surg. 1982;6:66–75
  8. Lai CL, Lam KC, Wong KP, Wu PC, Todd D. Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong. Cancer. 1981;47:2746–2755
  9. Wang TL, Yap IL, Tan YO. Hepatocellular carcinoma – a case series of 104 patients. Ann Acad Med Singapore. 1991;20:215–218
  10. Leyendecker JR, Dodd GD. Minimally invasive techniques for the treatment of liver tumors. Semin Liver Dis. 2001;21:283–291
  11. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer. 2004;40:1474–1484
  12. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–928
  13. Pawarode A, Tangkijvanich P, Voravud N. Outcomes of primary hepatocellular carcinoma treatment: an 8-year experience with 368 patients in Thailand. J Gastroenterol Hepatol. 2000;15:860–864
  14. Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 2002;36:1221–1226
  15. Martinez Cerezo FJ, Tomas A, Donoso L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol. 1994;20:702–706
  16. Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol. 1994;26:66–68
  17. Coll S, Sola R, Vila M. Treatment of tamoxifen in patients with advanced hepatocellular carcinoma. Results of a randomised placebo controlled trial (abstract). Hepatology. 1995;4:404A
  18. Castells A, Bruix J, Bru C, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology. 1995;109:917–922
  19. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol. 1997;8:117–136
  20. Mathurin P, Rixe O, Carbonell N, et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma – an impossible meta-analysis?. Aliment Pharmacol Ther. 1998;12:111–126
  21. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol. 2000;95:218–222
  22. Perrone F, Gallo C, Daniele B, et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des. 2002;8:1013–1019
  23. Barbare JC, Milan C, Bouche O. Treatment of advanced hepatocellular carcinoma (HCC) with tamoxifen: a phase III trial in 420 patients (abstract 511). Proc Am Soc Clin Oncol. 2002;21:138A
  24. Villa E, Dugani A, Fantoni E, et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res. 1996;56:3883–3885
  25. Chow PK, Huynh TH, Khin LW, Ooi PJ, Ong HS, Soo KC. Therapeutic Implications of the loss of estrogen receptor alpha and over-expression of androgen receptors in resected hepatocellular carcionoma. Aust NZ J Surg. 2000;70(S):95
  26. Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol. 1997;24:S1-65–S1-70
  27. Tan CK, Chow PK, Findlay M, Wong C, Machin D. Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift. J Gastroenterol Hepatol. 2000;15:725–729
  28. Chow P, Soo K. Hormonal therapy on hepatocellular carcinoma: the current scientific and clinical evidence. Asian J Surgery. 2000;
  29. Chow PK, Hung H, Soo KC. Re: Liu et al. – Estrogen receptor status in inoperable hepatocellular carcinoma. Am J Gastroenterol. 2001;96:1297–1298
  30. Liver Cancer Study Group of Japan . Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg. 1990;211:277–287
  31. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology. 2000;32:1224–1229
  32. Pawlik TM, Esnaola NF, Vauthey JN. Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. Liver Transpl. 2004;10:S74–S80
  33. Esnaola NF, Mirza N, Lauwers GY, et al. Comparison of clinicopathologic characteristics and outcomes after resection in patients with hepatocellular carcinoma treated in the United States, France, and Japan. Ann Surg. 2003;238:711–719
  34. Esnaola N, Vauthey JN, Lauwers G. Liver fibrosis increases the risk of intrahepatic recurrence after hepatectomy for hepatocellular carcinoma. Br J Surg. 2002;89:939–940(Br J Surg 2002;89:57–62)
  35. Esnaola NF, Lauwers GY, Mirza NQ, et al. Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg. 2002;6:224–232
  36. Vauthey JN, Lauwers GY, Esnaola NF, et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 2002;20:1527–1536
  37. Castells A, Bruix J, Bru C, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology. 1993;18:1121–1126

☆ Sources of funding: Not stated.

☆☆ For correspondence: Martin R Stockler, MBBS, NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia. E-mail: stockler@med.usyd.edu.au.

☆☆☆ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(05)00130-1

doi: 10.1016/j.ctrv.2005.07.005

Cancer Treatment Reviews
Volume 31, Issue 6 , Pages 491-495 , October 2005

Article Tools